ARTICLE | Clinical News
Afuresertib: Phase I/II data
June 13, 2016 7:00 AM UTC
Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial showed that once-daily oral afuresertib plus paclitaxel and carboplatin led ...